Target Name: NAT2
Review Report on NAT2 Target / Biomarker Content of Review Report on NAT2 Target / Biomarker
Other Name(s): N-acetyltransferase 2 | ARY2_HUMAN | Polymorphic arylamine N-acetyltransferase | Arylamide acetylase 2 | NAT-2 | Arylamine N-acetyltransferase-2 | N-acetyltransferase type 2 | AAC2 | Arylamine N-acetyltransferase 2 | arylamide acetylase 2 | Arylamine N-acetyltransferase | N-acetyltransferase 2 (arylamine N-acetyltransferase) | PNAT

The Role of NAT2 in Disease: A Potential Drug Target and Biomarker

An Overview of NAT2
N-Acetyltransferase 2 (NAT2), an enzyme present in humans, plays a crucial role in drug metabolism. It contributes to the phase II detoxification process by catalyzing the acetylation of various arylamine and hydrazine drug substrates. However, NAT2 is not only involved in drug metabolism; recent research has provided valuable insights into its association with diseases, making it a potential drug target and biomarker.

NAT2 in Drug Metabolism
NAT2 enzyme activity is responsible for the transformation of many therapeutic drugs. It catalyzes the transfer of an acetyl group from acetyl-coenzyme A to the target compound, resulting in its acetylation and subsequent detoxification. However, the activity level of NAT2 can vary significantly among individuals due to genetic polymorphisms. These polymorphisms give rise to different phenotypes, which can be classified as slow, intermediate, or fast acetylators.

NAT2 Polymorphisms and Drug Response
The genetic polymorphisms of NAT2 influence its enzymatic activity, which has implications for drug response and toxicity. Slow acetylators, typically carrying two variant alleles, exhibit reduced NAT2 activity, leading to a prolonged drug half-life and increased risk of adverse drug reactions. This phenomenon has been extensively studied in the context of certain antituberculosis drugs, such as isoniazid, where NAT2 slow acetylators require adjusted dosages to avoid toxicity.

In contrast, individuals with fast acetylator phenotypes experience rapid drug metabolism, potentially leading to subtherapeutic drug concentrations. This scenario has been observed in drugs like procainamide, where fast acetylators may require higher doses to achieve the desired clinical effect. Understanding an individual's NAT2 acetylator phenotype can aid in the personalized selection of drug dosages to optimize therapeutic outcomes while minimizing toxicity.

The Link Between NAT2 and Disease
Beyond its role in drug metabolism, recent studies have shed light on NAT2's involvement in various diseases. One such association is with colorectal cancer. Several reports have highlighted the potential impact of NAT2 polymorphisms on colorectal cancer risk. The slow acetylator phenotype of NAT2 has been implicated in an increased susceptibility to colorectal cancer development. This direct link opens up new avenues for research, exploring the underlying mechanisms and potential therapeutic interventions.

NAT2's association with other cancers, such as bladder, prostate, and pancreatic cancer, has also been investigated. Although the exact mechanisms remain unclear, studies have found correlations between specific NAT2 polymorphisms and increased cancer risk. These findings highlight the importance of NAT2 as a potential biomarker and therapeutic target in oncology.

Moreover, NAT2 has been implicated in drug-induced liver injury (DILI). Certain medications, such as antituberculosis drugs, can cause hepatotoxicity in susceptible individuals. The risk of DILI has been associated with NAT2 slow acetylator phenotypes. Identifying the acetylator status of patients prior to drug administration may help prevent adverse events and facilitate personalized medicine approaches.

NAT2 as a Drug Target
Understanding the role of NAT2 in disease has paved the way for exploring its potential as a drug target. Modulating NAT2 activity could be a valuable strategy in managing drug efficacy and toxicity. For instance, in cases where drug toxicity is associated with the slow acetylator phenotype, developing specific inhibitors of NAT2 could reduce the risk of adverse reactions.

Conversely, in situations where drug metabolism is rapid due to NAT2 fast acetylator phenotypes, strategies to enhance the enzyme's activity might be warranted. By altering the acetylation rate, therapeutic drugs could be metabolized more effectively, potentially improving treatment outcomes. However, it is essential to exercise caution and thoroughly evaluate the safety and effectiveness of these approaches, as intervening in NAT2 activity may have wider implications in drug metabolism beyond the target drug.

NAT2 as a Biomarker
The association of NAT2 polymorphisms with various diseases has paved the way for its potential use as a biomarker. Determining an individual's NAT2 acetylator phenotype can aid in tailoring drug regimens, optimizing dosing, and minimizing adverse drug reactions. In oncology, analyzing NAT2 status could help identify individuals at a higher risk of developing certain cancers, enabling early detection and targeted preventive measures.

N-Acetyltransferase 2 (NAT2) plays a vital role in drug metabolism, influencing drug response and toxicity. Its association with diseases, particularly cancer and drug-induced liver injury, highlights its potential as a drug target and biomarker. Future research should focus on unraveling the underlying mechanisms and developing targeted interventions to optimize therapeutic outcomes while reducing adverse events. The personalized medicine approach, incorporating NAT2 status into patient management, holds promise for improved treatment and prevention strategies.

Protein Name: N-acetyltransferase 2

Functions: Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens

The "NAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

NAT8 | NAT8B | NAT8L | NAT9 | NATD1 | Natural cytotoxicity triggering Receptor | NAV1 | NAV2 | NAV2-AS5 | NAV2-AS6 | NAV3 | NAXD | NAXE | nBAF complex | NBAS | NBAT1 | NBDY | NBEA | NBEAL1 | NBEAL2 | NBEAP1 | NBEAP3 | NBL1 | NBN | NBPF1 | NBPF10 | NBPF11 | NBPF12 | NBPF14 | NBPF15 | NBPF17P | NBPF18P | NBPF19 | NBPF20 | NBPF22P | NBPF25P | NBPF26 | NBPF3 | NBPF4 | NBPF5P | NBPF6 | NBPF7P | NBPF8 | NBPF9 | NBR1 | NBR2 | NCALD | NCAM1 | NCAM1-AS1 | NCAM2 | NCAN | NCAPD2 | NCAPD3 | NCAPG | NCAPG2 | NCAPH | NCAPH2 | NCBP1 | NCBP2 | NCBP2-AS1 | NCBP2AS2 | NCBP3 | NCCRP1 | NCDN | NCEH1 | NCF1 | NCF1B | NCF1C | NCF2 | NCF4 | NCF4-AS1 | NCK1 | NCK1-DT | NCK2 | NCKAP1 | NCKAP1L | NCKAP5 | NCKAP5-AS2 | NCKAP5L | NCKIPSD | NCL | NCLN | NCMAP | NCMAP-DT | NCOA1 | NCOA2 | NCOA3 | NCOA4 | NCOA5 | NCOA6 | NCOA7 | NCOR1 | NCOR1P1 | NCOR2 | NCR1 | NCR2 | NCR3 | NCR3LG1 | NCRUPAR | NCS1